Gut Microbiota and Cancer: From Pathogenesis to Therapy.
Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M. · 2019
Read Gut Microbiota and Cancer: From Pathogenesis to Therapy. by Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6356461.txt.
Introduction
Vivarelli and co-authors review gut microbes in cancer, from cause to treatment. Their review appeared in Cancers. Cancer is a complex, multi-cause disease. Gut bacteria help keep the host and gut in balance. They make compounds the body needs daily. Under imbalance, other bacteria can expand instead.
Those populations can release high levels of toxins. Toxins can spark inflammation and tumor formation. Microbes also act through the gut lining and immune system. Friendly probiotic bacteria protect against tumor genesis. Trials now test them against imbalance in patients. The review covers microbe roles in specific cancers. It also covers how microbes affect cancer drugs. The gut emerges as a partner in oncology care.
Catalog record
| CREATOR | Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gut Microbiota and Cancer: From Pathogenesis to Therapy By Silvia Vivarelli, Rossella Salemi, Saverio Candido, Luca Falzone, Maria Santagati, Stefania Stefani, Francesco Torino, Giuseppe Luigi Banna, Giuseppe Tonini, Massimo Libra Published in: Cancers DOI: 10.3390/cancers11010038 ABSTRACT Cancer is a multifactorial pathology and it represents the second leading cause of death worldwide. In the recent years, numerous studies highlighted the dual role of the gut microbiota in preserving host’s health. Gut resident bacteria are able to produce a number of metabolites and bioproducts necessary to protect host’s and gut’s homeostasis. Conversely, several microbiota subpopulations may expand during pathological dysbiosis and therefore produce high levels of toxins capable, in turn, to trigger both inflammation and tumorigenesis. Importantly, gut microbiota can interact with the host either modulating directly the gut epithelium or the immune system. Numerous gut populating bacteria, called probiotics, have been identified as protective against the genesis of tumors. Given their capability of preserving gut homeostasis, probiotics are currently tested to help to fight dysbiosis in cancer patients subjected to chemotherapy and radiotherapy. Most recently, three independent studies show that specific gut resident species may potentiate the positive outcome of anti-cancer immunotherapy. The highly significant studies, uncovering the tight association between gut microbiota and tumorigenesis, as well as gut microbiota and anti-cancer therapy, are here described. The role of the Lactobacillus rhamnosus GG (LGG), as the most studied probiotic model in cancer, is also reported. Overall, according to the findings here summarized, novel strategies integrating probiotics, such as LGG, with conventional anti-cancer therapies are strongly encouraged. 1. INTRODUCTION Cancer is the second leading cause of death worldwide [1,2]. Cancer formation is the result of the stochastic intracellular accumulation of spontaneous mutations during DNA replication, combined with the environment exposure and lifestyle habits, both able to significantly influence cancer risk [3,4]. For example, the exposure to infectious agents, UV radiation and toxic substances, individual diet and lifestyle, strongly influences cancer rise, although the risk mainly depends on the dose, the duration and the combination of such injuries, coupled with the individual genetic background [5]. In the recent years, numerous evidences pointed towards the central role of commensal bacteria colonizing body surfaces as key determinants of health or pathologic conditions, including cancer [6]. Among the human symbiotic microbial populations, the gut microbiota is the most extensively studied and it deeply influences host’s homeostasis [7]. Gut microbiota is the name given to the heterogeneous population of commensal microorganisms, mainly bacteria, but also fungi, archaea and viruses, populating the intestinal tract, mostly the large intestine, and it can be considered as one factor to which we are persistently exposed, at high doses, throughout the entire lifespan [8]. Among a 1000 of different bacterial species within the gut microbiota, the highly represented ones are the Firmicutes and Bacteroidetes phyla [9]. The gut microbiota performs a number of vital functions, including production of vitamins, metabolization of dietary compounds, protection against the expansion and systemic infiltration of gut pathogens [10,11,12]. The gut microbial balance has a key role in the correct fulfilment of all these pivotal metabolic functions. Any imbalance in this delicate equilibrium may lead to an impaired microbiota, condition called dysbiosis, linked with several human pathologies, including cancer [13]. The gut microbiome, defined as the whole genome of the host’s gut microbiota, encodes 100-fold more genes than the human genome [14]. Within the last decade, the advent of metagenomics, combining next-generation sequencing (NGS) with computational analysis of the 16S rRNA amplicons, allowed to characterize both diversity and abundance of the gut microbiome. Progresses in metagenomics studies, together with the advancements in transcriptomics and metabolomics, allowed to describe the impact of individual bacterial species on host’s health [15,16]. That represents a step forward, from descriptive microbiome composition analyses, to functional studies, which are nowadays helping to understand the true impact of the microbiome architecture on human health [17,18]. However, this research is at its beginning, and all these growing number of associative and functional studies need to be further corroborated by results obtained from larger clinical studies [19]. Among all the pathologies linked with the gut microbiome, tumorigenesis is one of the mostly studied. The link has been found both with local gastro-intestinal cancers, as well as with other distal tumors [20]. Metabolomics and metagenomics studies highlighted the dual role of the gastro-intestinal microbiome in cancer prevention, tumorigenesis and anti-cancer therapy [21]. In fact, the gut microbiome can either be tumor-suppressive or oncogenic [22,23]. Although this link is studied since long ago, it is only partially characterized. In fact, all the current knowledge emphasizes the complexity and bidirectionality of the connection existing between microbiome and cancer. As a consequence, cancer development may alter the microbiome and, in turn, microbiome changes may affect cancer progression [24]. In this review, the up-to-date studies uncovering the tight link between gut microbiota and tumorigenesis will be described. Moreover, the importance of probiotics supplementation with anti-cancer therapy will be also discussed, including the key role and the future applications of a probiotic model studied in cancer, Lactobacillus rhamnosus GG (LGG), often used to treat cancer patients’ intestinal dysbiosis. 2. GUT MICROBIOTA AND HOST’S TUMORIGENESIS 2.1. Gut Microbiota and Host Crosstalk The gut is bidirectionally connected with the nervous system through the so-called “gut-brain axis” (GBA), which includes the central nervous system (CNS), the autonomic nervous system (ANS), the enteric nervous system (ENS), the hypothalamic pituitary adrenal (HPA) axis and the entero-endocrine system (EES). Hormones and neuro-hormones secreted at each of these listed GBA levels may modulate the gastro-intestinal digestive and metabolic activities, and vice-versa [25]. For that reason, the gut represents a complex interface between the gastro-intestinal resident microbiota and the human body. There is a bidirectional crosstalk between gut resident microbes and host’s GBA, in which the gut functions as the communication gatekeeper [26]. In particular, it is known that host’s hormones and neuro-hormones are able to modify the gut microbiome composition, as during stress response [27]. Importantly, the gastro-intestinal entero-endocrine cells secrete over 30 different peptide hormones, involved in several functions, such as gastro-intestinal motility, digestive functions and neuromodulation [28]. A number of these hormones can be sensed by the gut bacteria, as in the case of leptin and ghrelin, which, in turn, finely tune the gut microbiota composition in rodents [29,30]. In the same way, the gut microbial population secrete active molecules which can be sensed by the gut cells and whose effects are then transduced to the GBA [27]. In fact, it has been widely studied that the gut microbiota may produce or transform molecules affecting several aspects of human health, including: host’s metabolism modulation, gut barrier integrity maintenance, xenobiotics and drug metabolism, protection against gastro-intestinal pathogens and host’s immune system modulation [31,32,33,34]. With regards to the host’s metabolism, it is known that certain commensal bacteria produce essential micronutrients, such as vitamin K and various components of vitamin B. Also, members of the Bacterioides family are able to synthetize the anti-diabetic compound linoleic acid, to catabolize secondary bile acids and to break down phenolic compounds. Moreover, a number of gut commensals can modify small aminoacids into signaling molecules, as for example histidine to histamine or glutamate to γ-aminobutyric acid (GABA) [35]. Additionally, it has been reported that gut